Histological and Endoscopic evaluation of Remission induced by Infliximab in moderately to severely active ulcerative Colitis Patients.

Trial Profile

Histological and Endoscopic evaluation of Remission induced by Infliximab in moderately to severely active ulcerative Colitis Patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Aug 2013

At a glance

  • Drugs Infliximab (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms HERICA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 May 2012 Actual patient number (21) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top